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1. Introduction 
Cell and gene-based therapies (CGTs) represent a novel therapeutic modality that have the 
potential to address the significant medical challenges associated with chronic, age-related 
clinical indications and provide a treatment option for a range of unmet medical needs. There 
are, however, numerous processing and manufacturing challenges that must be addressed 
before such therapies are considered commercially and clinically viable. A significant 
challenge associated with the manufacture of such therapies is ensuring cell quality and that 
the  product’s critical quality attributes (CQAs) [1] are retained throughout the entire 
bioprocess, from initial cell isolation through to delivery and administration to a patient. Unlike 
traditional biopharmaceutical manufacture, manufacturing paradigms for CGTs may involve 
an autologous (patient-specific), allogeneic (universal donor) or haplobank approach.  
 
An important aspect of all CGT bioprocessing is biopreservation. This enables the creation of 
cell banks (master and working cell banks for allogeneic product manufacture or storage banks 
for patient specific material such as cord blood). This can uncouple the expansion and/or 
manipulation of cells from the clinic, creating product shelf-life and  facilitates the 
transport/storage of any product intermediates (e.g. newly isolated cells or even  viral vectors) 
too [2] Fig 1. Indeed, where the process necessitates transfer of cellular material from the clinic 
to an off-site facility for processing and/or expansion, biopreservation measures will be critical 
to product quality and success. This places particular emphasis on the appropriate selection of 
biopreservation methods, with a need to demonstrate that they do not adversely impact the 
product’s CQAs. Moreover, the biopreservation methodology needs to align with the business 
and distribution model to ensure commercial success and should occur during early stages of 
development given the integral role biopreservation plays in the logistical and manufacturing 
bioprocessing considerations [3]. Biopreservation also determines the level of at-clinic 
processing, e.g. will the cells need to be thawed prior to administration or are they preserved 
and subsequently delivered at ambient temperature. Thus, in many CGT processes, it is likely 
that biological material will require at least one biopreservation step, if not more (Figure 1).  
This will exacerbated for gene therapy products where other biological material (e.g. viral 
vectors) are also likely to undergo an independent preservation process prior to their addition 
to the cellular material. 
 
2. Types of biopreservation 
Biopreservation is often used synonymously with cryopreservation. However, whilst reviewing 
regulatory submissions for mesenchymal stem cell therapies to the FDA in 2012 reveals that 
freezing is certainly a key biopreservation method, with more than 80% of submissions 
involving a frozen product [4]. It is not the only biopreservation method that is being 
considered for commercial and clinical use. Indeed, given the need to retain the product CQAs 
and that multiple different manufacturing/distribution models are likely to be employed for 
CGTs (e.g. autologous, allogeneic and haplobank), it has become increasingly important to 
consider other types of biopreservation for the storage and transportation of biological material. 
This includes hypothermic preservation (i.e. ‘cell pausing’) at either ambient [5-7] or 
refrigerated chilled temperatures [8, 9]. Ultimately, the decision as to which biopreservation 
method is most appropriate will need to take into account which method has the least effect on 
the product’s CQAs whilst remaining both commercially, clinically and logistically viable.  
 
2.1 Cryopreservation 
Freezing is the most common biopreservation method employed in CGT processes [2], with 
the first successful cryopreservation taking place in 1949 with spermatozoa in glycerol [10]. 
Standard cryopreservation practise of cellular material usually involves a two-step controlled 
rate freezing (CRF) process: (1) the controlled reduction of the temperature of the cellular 
material to -80˚C at a rate of 1 ˚C /min, followed by, (2) reducing the temperature even further 
to ≤ -150˚C usually by placing into liquid nitrogen, its vapour phase for long-term storage. This 
method of CRF has been demonstrated for both millilitre cryovials and in bags of large volumes 
(>100 mL) for both adult stem cells [11] and other mammalian cells [12, 13]. It has also been 
successfully employed for the human fibroblast-derived dermal substitute Dermagraft 
(Advanced Biohealing, USA) [14] in addition to the hMSC product, Prochymal, which has 
received conditional approval in New Zealand and Canada, and is available in the United States 
under an Expanded Access Programme for treatment of acute GVHD in children [15, 16]. In 
the Health Canada summary basis of decision (SBD), Prochymal’s shelf-life is identified as 2 
years at ≤ -135˚C [16].  
 
Cryopreservation usually enables high cell recovery, with > 90% cell viability immediately 
post-thaw. However, this is cell and process-dependent and delayed onset apoptosis can be 
caused [17] which is not detected immediately post-thaw by assays such as trypan blue 
exclusion. Indeed, there have been studies which, for example, have demonstrated that human 
embryonic stem cells are sensitive to cryopreservation with a relatively low recovery post-
thaw, in addition to changes in cell phenotype resulting in poor outcomes for cell functionality 
[18, 19]. Moreover, whilst some studies have demonstrated an adverse effect on hMSC 
functionality with respect to T-cell suppression, response to IFN-γ, lower production of anti-
inflammatory mediators and impaired blood regulatory properties immediately post-thaw for 
hMSCs compared with actively proliferating hMSCs [20, 21], yet others have demonstrated 
that cryopreservation does not adversely affect the viability, immunomodulatory properties or 
differentiation capacity [22]. For example, Cruz et al. (2015) reported equivalency between 
cryopreserved and non-cryopreserved hMSCs [23]. François et al. (2012), one of the groups 
who reported that hMSCs were adversely impacted by cryopreservation did note that thawed 
hMSCs recovered their immunomodulatory functionality 24 hours post-culture [20] suggesting 
that a cell-recovery process may need to be incorporated post-thaw to retain viability and, more 
importantly, ensure functionality of the cryopreserved cells. If indeed this is necessary for the 
product to retain its CQAs, this increases process complexity and costs, with a particular 
consideration as to where the cell-recovery process step is conducted. Moreover, the 
differences between the aforementioned studies could also potentially be explained by 
differences in the cell handling, cryopreservation medium formulations, freezing protocols and 
thawing procedures. That the thawing process is often badly, if at all, controlled and that this 
may be responsible for some of the damage perceived to be caused by cryopreservation is now 
starting to be recognised by the community. For example, at ISCT 2017, one report highlighted 
the interplay between cooling rate and thawing rate for T cell recovery post-thaw [24]. To 
address this, rapid and specialised thawing devices are being developed such as the ThawSTAR 
from Medcision and VIA Thaw by Asymptote   
As well as CRF, vitrification can also be used to cryopreserve cells. This involves the rapid 
cooling of the cellular material, thereby avoiding formation of both extra- and intracellular ice 
crystals [25] and generating amorphous ice. although vitrification has been employed 
successfully for multiple cell types, in particular, colonies of human embryonic stem cells 
(hESCs), where vitrification has resulted in high levels of viability and retention of 
functionality post-thaw [26-28].  However, this method uses significantly higher levels of 
cryoprotective agent (CPA) than in CRF to prevent ice crystallisation, and enable vitrification 
at a higher glass transition temperature and an achievable cooling rate. Also, although efforts 
are ongoing to generate larger scale vitrification methods, the high cooling rates needed mean 
that only small volumes (typically 1-20ul) may be vitrified at once [3], making this an 
unattractive option for freezing of cell therapies currently.  
 
2.1.1 Cryopreservation challenges 
Although cryopreservation is currently considered to be the industry standard for CGT 
biopreservation, there are numerous challenges and considerations. Primarily, it is critical to 
understand the implications of cryopreservation on the product’s CQAs. This requires in-depth 
understanding about the product’s biological attributes, mechanism of action and safety profile. 
There are also concerns with the use of liquid nitrogen in a GMP environment, where it may 
compromise clean room air quality given the potential for contamination with microorganisms, 
particulates and debris during transport and storage [29-31]. To use liquid nitrogen in a clean 
GMP facility would require the use of validated sterilisation and/or filtration methods [31, 32]. 
This can, however, be overcome by omitting the use of liquid nitrogen and using an electrically-
powered Stirling cryocooler which has been used for multiple human cell types including 
hESCs and alginate-encapsulated liver cells [31]. 
 
The most significant concern with cryopreservation is the use of CPAs, in particular the 
intracellular CPA, dimethyl sulphoxide (DMSO). DMSO, the most commonly used CPA, is 
classified by the FDA as a class 3 solvent [33] and is considered to be toxic to both cells and 
patients at room temperature . It is recommended that patients do not receive more than 1g/kg 
body weight/day of DMSO, with a maximum permissible limit of 50 mg/day [34, 35]. Such 
concerns and restrictions have been put in place due to the toxicology issues associated with 
DMSO [36]. This concern is exacerbated with vitrification given the need to significantly 
increase the CPA concentrations to avoid ice crystal formation. Although DMSO is still the 
most commonly used CPA, alternatives are being considered for the cryopreservation of 
mammalian cells which pose a lower toxicity risk including trehalose [37] and sucrose [38]. 
These CPAs provide a similar level of protection to cellular material during freezing, however 
the challenge with these CPAs is their inability to penetrate the cell. The delivery of these CPAs 
into mammalian cells requires an additional process step such as electroporation or 
permeabilisation [37, 39, 40]. 
 
2.2 Hypothermic storage 
Whilst it is generally recognised and accepted that for long-term storage (months/years), 
cryopreservation remains the most cost-effective and scientifically robust method, there are 
genuine concerns about the use of cryopreservation for short-term storage and transport due to 
the potential for ice crystal formation and potentially toxic CPA concentrations. A potential 
alternative biopreservation method which is amenable for short-term requirements (e.g. days) 
is hypothermic storage. This includes chilled preservation, a process where the temperature is 
reduced to 2-8˚C and ambient preservation (e.g. room temperature). Refrigerated preservation 
is currently used for the transfusion of red blood cells (RBCs) for the treatment of severe 
anaemia. RBCs can be stored at refrigeration temperature for up to 42 days within an additive 
solution, where they can then be transported to the site of administration upon request [41]. 
Moreover, refrigeration temperatures have also been used for the storage and transportation or 
whole organs prior to transplantation [42, 43].  
 
Much of the research and development activity for chilled preservation relates to storage and 
transportation of whole organs and red blood cells. However, with the increasing promise of 
CGTs, there has been renewed interest in short-term chilled preservation for CGT cell 
candidates, in particular stem cells. The commercial hypothermic preservation medium 
solution HypoThermosol Free Radical Solution (BioLife Solutions, USA) has been used for 
the successful storage and preservation of a range of cell types including hMSCs [44] and 
differentiated human neural stem cells (hNSCs) [45]. In the case of hMSCs, the cells retained 
> 85% viability after 96 h when stored at 4˚C [44], and for the differentiated hNSCs, the cells 
were seeded onto cellular collagen constructs and placed into a range of different medium 
compositions for storage at 4˚C for 48 h. The cells which were preserved in the HTS-FRS 
medium composition demonstrated the least cell death (<10%), even lower than cells which 
were preserved using DMSO under cryogenic conditions [45]. Indeed, recently, HTS was used 
for TiGenix’s phase 1 clinical trial study where expanded allogeneic adipose-derived stem cells 
stored in HTS were administered to patients [46]. 
 Although chilled preservation will not be used as a long-term biopreservation method, it has 
demonstrated significant potential for its ability to suitably preserve cells at refrigerated 
temperatures for time periods accounting for transportation across countries. Transporting a 
CGT product between countries a significant distance apart can take up to 24 h, however this 
does not take into account transportation delays, customs checks and potential clinical 
complications. As such, the longer the cells can be shown to demonstrate the retention of their 
CQAs in the biopreservation formulation, the more flexibility this provides to the overall 
process [3]. The additional advantage of this type of preservation in comparison to 
cryopreservation is that much of the clinical infrastructure, logistics and supply chain aspects 
to enable chilled storage and transportation is already in place. As such, significant changes to 
current practice and facilities will unlikely be required. 
 
Ambient temperature preservation simplifies the process even further compared to chilled 
preservation and does not require any additional infrastructure to maintain refrigerated or 
cryogenic temperatures, thereby reducing cost and process complexity. Unlike 
cryopreservation and, to a lesser extent, chilled preservation, the research with ambient 
temperature preservation is not as extensive and has only become an area of interest in light of 
the potential advantages this preservation method confers over the aforementioned preservation 
techniques. The potential of this technique is demonstrated by Chen et al. (2013) who 
demonstrated that they were able to store hMSCs and mouse ESCs (mESCs) inside alginate 
hydrogels for 5 days in ambient conditions in an air-tight environment. Cell viability post-
preservation was found to be 80% and 74% for the hMSCs and mESCs respectively [47]. 
Similarly, Swioklo et al (2016) showed human adipose-derived stem cells could be 
encapsulated and stored at a range of temperatures, from 4-23C, although 15C was found to be 
the optimal [48]. The disadvantage to this method however is the need for a cell retrieval step 
which increases process complexity and will likely need to be undertaken at- or near-clinic. 
Ambient temperature cell preservation has also been reported for hair follicles which 
demonstrated adequate graft recovery post-preservation [49]. Additionally, Hunt et al. (2005) 
have reported the successful preservation of other mammalian cell types (CHO and HEK293 
cells) at temperatures ranging between 6-24˚C for > 3 days [6].  
 
As with chilled preservation, ambient temperature preservation is a potential technique that can 
be used for pooling of cells during the process (for example post-harvest from culture devices 
awaiting downstream processing), or indeed, used for storage and transportation to site of 
clinical administration. However, it is critical that the acceptable temperature ranges and 
timeframes are identified and validated, with the validated conditions making allowances for 
potential processing and/or transport delays. There should also be consideration of effect of 
multiple preservation steps (if employed) during a process and the cumulative effect of ambient 
temperature preservation throughout the process. Greater product and process understanding 
will facilitate the consideration of multiple processing options and increase overall process 
flexibility. 
 
2.2.1 Hypothermic preservation challenges 
There are two key challenges for chilled preservation. The first has been alluded to previously 
and relates to the maximum time period it can be effectively used, and importantly, validated 
as a biopreservation method. Although there has been promising research data that suggests 
chilled preservation in conjunction with specifically designed hypothermic medium 
preservation solutions can retain cell viability and functionality across multiple days, there is a 
greater burden of evidence required for validation.  
 
The other key challenge with chilled preservation, and exacerbated for ambient preservation 
(discussed later), is the fact that chilled preservation only slows and does not arrest cellular 
functions, activity and metabolism. This results in the potential build-up of deleterious 
metabolites and, perhaps more critically, the depletion of important substrates required for cell 
maintenance [50, 51]. It should also be noted that although chilled preservation does not result 
in cellular damage arising from ice crystal formation or suffer from CPA toxicity issues 
experienced with cryopreservation, there are concerns about chilled preservation resulting in 
cold-induced cell damage [52]. This risk of cell damage is intrinsically linked to the 
preservation time, with a greater risk of cell damage and decreased viability with longer 
preservation times [3]. There are also concerns with chilled preservation that once rewarmed 
to the appropriate administration temperature, the increased production of free radicals and 
other deleterious metabolites may result in delayed onset cell death, which may not be 
noticeable immediately but potentially take hours or days to become apparent [53]. 
 A key challenge with ambient temperature preservation is demonstrating the utility and 
efficacy of such a preservation at industrial scales and practical terms. Given the relative 
infancy of this area of research, it is expected further studies will be conducted outlining the 
promise and potential of this technique. At present however, there is little that has been 
conducted with relevant cell types with a focus on CGT manufacture and bioprocessing to be 
able to make a strong scientific case for ambient temperature preservation. However, should it 
be scientifically feasible, the advantages of ambient temperature preservation are substantial 
and would significantly reduce process, storage and transportation costs.  
 
3. Translational insight 
Biopreservation of biological material for CGTs is often considered too late in process 
development or not given its due attention because of what is often perceived as other, ‘more 
important’ development activities. However, for effective CGT process development, 
translational research activity with respect to biopreservation given its pivotal role in process 
development, storage, transportation and overall business model. It is critical to identify early 
in process development which biopreservation technique(s) (cryo-, chilled, or ambient 
preservation) is the most appropriate for the CGT. Cryopreservation will remain the only 
feasible biopreservation technique for long-term storage (months/years), however, both chilled 
and ambient preservation methods provide additional process flexibility, particularly with 
respect to interprocess pooling/storage and transportation across manufacturing and clinical 
facilities. As with any CGT process, it is unlikely that a universal biopreservation approach 
will be appropriate in all cases and ultimately needs to be determined after thorough 
development activity identifying effects of biopreservation on the product’s CQAs and the 
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